Artelo Biosciences, Inc. (ARTL)
Chart Events
Performance Outlook
| Previous Close | 0.3023 |
| Open | 0.3109 |
| Bid | 0.3125 x 800 |
| Ask | 0.3199 x 1000 |
| Day's Range | 0.3102 - 0.3200 |
| 52 Week Range | 0.2810 - 1.3200 |
| Volume | |
| Avg. Volume | 1,405,270 |
| Market Cap | 13.528M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3980 |
| Earnings Date | Jan 12, 2022 - Jan 17, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.08 |
- GlobeNewswire
Artelo Biosciences Presents Positive Pre-Clinical Results of ART26.12, a Novel FABP5 Inhibitor, in Alleviating Chemotherapy-Induced Pain
Presentation delivered by Professor Saoirse O’Sullivan at the 32nd Annual ICRS Symposium in Galway, Ireland on Sunday, June 26thSOLANA BEACH, Calif., June 27, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, announced that Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo Bios
- GlobeNewswire
Artelo Biosciences Selected for Oral Presentation at the 32nd Annual ICRS Symposium in Galway, Ireland
SOLANA BEACH, Calif., June 24, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, announced that Professor Saoirse O’Sullivan, Artelo’s Vice President of Translational Sciences, has been selected for an oral presentation at the 32nd International Cannabinoid Research Society (ICRS) Symposium, on Sunday, June
- GlobeNewswire
Artelo Biosciences to Present at the LD Micro Invitational XII on June 7th
SOLANA BEACH, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. “Artelo” or the “Company”) (NASDAQ: ARTL), a clinical-stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today announced that Gregory D. Gorgas, Chief Executive Officer of Artelo, will be presenting at the LD Micro conference which is being held on June 7– 9, 2022, at the Four Seasons Westlake Village, California. Mr. Gorgas is scheduled
